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Abstract
Objective: The objective of this EBM review is to determine whether or not Crocus Sativus L. is
as effective as Fluoxetine for the treatment of mild to moderate depression in adults aged 18-55.
Study design: Systematic review of three English language, double-blind randomized controlled
trials published between 2005-2007.
Data source: Three double-blind randomized controlled trials published in peer-reviewed
journals comparing the effectiveness of Crocus Sativus L. vs. Fluoxetine or placebo for the
treatment of mild to moderate depression in adults were found using PubMed and Ebscohost.
Outcomes measured: In all three articles the outcomes measured were improvement in
depression symptoms based on 17-item Hamilton Depression rating scale.
Results: Two studies that compared saffron to fluoxetine found that saffron was as effective as
fluoxetine for the treatment of mild to moderate depression. One study that compared saffron to a
placebo found that patients in the saffron group had a significant improvement in their symptoms
compared to the placebo group.
Conclusions: According to the three studies conducted, Saffron can be used as an alternative for
the treatment of mild to moderate depression in adults.
Keywords: Crocus sativus; Saffron; Depression; Fluoxetine
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INTRODUCTION
Depression is a major problem in the United States, affecting about 5 percent of the
adults.1 In fact, depression is one of the most common psychiatric conditions, and it is estimated
that it will represent the second largest disease burden worldwide by the year 2020.1,2 American
Psychiatric Association defines depression as a heterogeneous disorder often manifested with
symptoms at the psychological, behavioral and physiological levels that is thought to result from
biochemical changes in the brain.3 According to the Center for Disease Control (CDC), in 2003,
national health expenditures for mental health services were estimated to be over 100 million
dollars, and depression is estimated to cause 200 million lost workdays each year at a cost to
employers of 17 to 44 billion dollars.4 There are many different medications available for the
treatment of depression, including monoamine oxidase inhibitors (MAOIs), tricyclic
antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), selective norepinephrine
reuptake inhibitors (SNRIs) and many more. Although these medications can be very effective,
there are many side effects associated with them. Some side effects include anticholinergic
affects, sexual dysfunction, cardiac arrhythmias, orthostatic hypotension, and many more. Also,
about one-third of patients receive no benefit and one-third does not experience complete
remission after monotherapy with antidepressants.2
In the western society medications are the mainstay of treatment for depression, however
in Persian countries herbs have been used for their antidepressants affects for thousands of years.
Crocus Sativus, a very expensive spice also known as saffron has been used around the world for
many years for its antidepressants effects. The major benefits of spices and natural herbs are that
there are no side affects associated with them and they are relatively safe. Although this spice
has been used around the world, especially in the Middle East for thousands of years there have
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been no studies done to show its effectiveness. In the recent years, researchers in Iran decided to
test the effectiveness of this spice versus fluoxetine, a widely used SSRI for depression.
OBJECTIVE
The objective of this systematic review is to determine whether Crocus Sativus (saffron)
is as effective as fluoxetine for the treatment of mild to moderate depression in adults aged 1855.
METHODS
Three double blind, randomized controlled studies were chosen for this review based on
certain specific criteria. The population that was included in these studies was men and women
between the ages of 18-55 with mild to moderate depression based on the Diagnostics and
Statistical Manual of Mental Disorders (DSM-IV) criteria. The intervention that was studied was
the spice crocus sativus, more commonly known as saffron for the treatment of mild to moderate
depression in these patients. Two of the articles compared saffron to the drug fluoxetine, a
classic SSRI used to treat depression. One article compared saffron to placebo in order to study
the effectiveness of the spice on these patients. The symptoms and severity of disease of the
subjects were recorded at the beginning of the study using the Hamilton Depression rating scale
(17-item HAM-D scale) and periodically throughout the study. All studies measured the
improvement of depression symptoms using the same scale.
Some keywords used in the search for RCT’s included depression, crocus sativus,
saffron, and fluoxetine. The chosen articles were all written in English and published in peerreviewed journals between 2005 and 2007. The articles were found using PubMed and
EBSCOHOST databases, and chosen based on their relevance to the clinical question and for
their emphasis on patient-oriented evidence based medicine. The inclusion criteria consisted of
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males and females between the ages of 18-55 with mild to moderate depression with a baseline
HAM-D 17 item score of at least 18 and ≤ 25. Exclusion criteria consisted of anyone under the
age of 18 and over the age of 55, anyone with current cognitive disorder in the last year, or
anyone with current or past history of bipolar disease, schizophrenia, schizotypal personality
disorder, and/or borderline personality disorder. Patients who scored greater than 2 on the
suicide item of the HAM-D scale, and those with suicidal ideation were excluded as well.
Pregnant women, or women of child-bearing age not on accepted form of birth control were also
excluded (Table 1). In the Basti et el. study the statistical data reported were P-value, RBI, ABI,
and NNT. In Noorbala and Moshiri studies only a P-value was reported.
Table 1- demographics and characteristics of included studies
Study

Type

#Pts

Age (yrs)

Basti
(2007)

Double 40
blind
RCT

18-55

Moshiri
(2006)

Double 40
blind
RCT

18-55

Inclusion
criteria
Pts who met
the DSM-IV
criteria for
major
depression.
pts have a
baseline
HAM-D 17
item score
of at least
18 and ≤ 25.
Pts who
met the
DSM-IV
criteria for
major
depression.
pts have a
baseline
HAM-D 17
item score
of at least

Exclusion criteria

W/D

Interventions

Current cognitive disorder in
the last year, current/past
history of bipolar disease,
schizophrenia, schizotypal
personality disorder and
border line personality
disorder.
Excluded if pt posed a
significant risk of suicide.
Pregnant woman or woman
not using medically approved
method of birth control were
excluded.
Current cognitive disorder in
the last year, current/past
history of bipolar disease,
schizophrenia, schizotypal
personality disorder and
border line personality
disorder.
Excluded if pt posed a
significant risk of suicide.
Pregnant woman or woman
not using medically approved

2

C. Sativus 15
mg bid or
fluoxetine 10
mg bid.

4

C. Sativus
30mg/day or
Placebo
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18
Noorbala
(2005)

Double 40
blind
RCT

18-55

method of birth control were
excluded.
Pts who met Current cognitive disorder in
the DSM-IV the last year, current/past
criteria for
history of bipolar disease,
major
schizophrenia, schizotypal
depression. personality disorder and
pts have a
border line personality
baseline
disorder.
HAM-D 17 Excluded if pt posed a
item score
significant risk of suicide.
of at least
Pregnant woman or woman
18
not using medically approved
method of birth control were
excluded.

2

C. Sativus
30mg/day or
Fluoxetine 20
mg/day

OUTCOMES MEASURED
All three studies measured the improvement of depression symptoms using the Hamilton
Depression scale. In all three of the studies, all patients had a baseline psychiatric evaluation, a
structured diagnostic interview and a medical history. Patients were randomized to receive either
a capsule of C. sativus or fluoxetine in two of the studies, and a placebo pill in the third study.
The patients were then followed and evaluated by a psychiatrist after 1, 2, 4, 6, and 8 weeks in
one study1 and 1, 2, 4, and 6 weeks in the other two studies.2,3 The principle measure of the
outcome was the 17-item HAM-D scale; the mean decrease in HAM-D score from baseline was
used as the main outcome measure of response of depression to treatment.1,2,3
RESULTS
In the study done by Basti et el, forty adult patients with major depression that scored at
least 18 and ≤ 25 on the HAM-D depression scale participated in the trial. These 40 individuals
were randomly assigned into two groups, 20 of them received fluoxetine 10 mg bid, and the
remaining 20 received C. Sativus capsule 15 mg bid. No significant differences were identified
between the two groups in regards to patient demographics, age and gender. There were 2
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withdraws, one from each group, thus 38 people completed the trial. The outcomes were
presented as dichotomous data and intention to treat analysis was used with last observation
carried forward. The Hamilton Depression Rating Scale was used to compare the two groups,
and there were no significant differences in the HAM-D scale between the two groups in week 0,
the baseline evaluation (t=0.86, d.f=38, P=0.39). In this study the percentage of responder was
determined as 50% drop in the Hamilton Depression Rating Scale Score. Outcome measured was
the mean decrease in HAM-D score from baseline as the measure of response of depression to
treatment, so this negative value means that for every 10 patients that took crocus sativus there
was one fewer 50% mean decrease from baseline in HAM-D score compared to fluoxetine.
There were no significant differences between two treatments in terms of the percentage of
responders, which is defined as at least 50% drop in the Hamilton Depression Rating Scale;
fluoxetine 85% and Crocus Sativus 75% (Table 2). The data was not statistically significant
(P=0.30). The relative benefit increase was calculated ot be -0.118, the absolute benefit increase
was found to be -0.1, and the numbers needed to treat was calculated to be -10 (Table 2). Thus,
this study found no significant differences on the change of scores of the Hamilton Depression
Rating Scale at week 8 compared to baseline in the two groups, meaning Crocus Sativus is as
effective as fluoxetine in the treatment of mild or moderate depression. Ten side effects were
observed over the 8 week study, including anxiety, decreased appetite, increased apetite, sexual
dysfunction, tremor, nausea, headache, sweating, heart pounding, and insomnia. However, the
difference between the crocus sativus and fluoxetine in the frequency of side effects was no
significant.1
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Table 2: Efficacy of Saffron vs. Fluoxetine
Study

Percentage Percentage P-value
RBI
of
of
responders responders
in
in Crocus
Fluoxetine sativus
group
group.
Basti et el
85%
75%
P = 0.30
-0.118
RBI = relative benefit increase, ABI= Absolute benefit increase
NNT = Numbers needed to treat

ABI

NNT

-0.1

-10

Noorbala et el study was a 6 week randomized and double-blind clinical trial that
compared the effectiveness of crocus sativus to fluoxetine for the treatment of mild to moderate
depression in adults. Forty outpatient adults who me the criteria for mild to moderate depression
with a baseline HAM-D scale score of at least 18 participated in this study. Patients were
randomly divided into two groups, one group received capsule saffron 30mg/day, and the other
group received fluoxetine 20mg/day. The patients were assessed by a psychiatrist at baseline,
and then at 1, 2, 4, and 6 weeks after the medication was started. The data in this study was
continuous, and to compare the two groups at baseline and the outcome of two groups at the end
of the trial, an unpaired Student’s t-test with a two-sided P-value was used. Differences were
considered significant with P<0.05. In the fluoxetine group the drop in the HAM-D scale score at
the end of week 6 compared to baseline was -15.00 ± 5.88, and in the saffron group it was -12.20
± 4.67 (Table 3). The P value was calculated as 0.10, thus no significant differences was
observed on the change of scores of the HAM-D scale at week 6 compared to baseline in the two
groups (Table 3). Over the course of the study nine side effects were observed, including
anxiety, decreased appetite, increased appetite, sedation, nausea, headache, sexual dysfunction,
tremor, and sweating. Although patients in the saffron groups reported slightly less side effects
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compared to the fluoxetine group, there were no significant differences between the side effects
in the two groups based on the p-values (table 4).3

Table 3- Efficacy of Saffron vs. fluoxetine
Study
Noorbala et el.

Drop in HAM-D
score in fluoxetine
group
-15.00 ± 5.88

Drop in HAM-D
score in saffron
group
-12.20 ± 4.67

P- Value
0.10

Table 4: Side effects of saffron vs. fluoxetine
Side Effects
Anxiety
Decreased appetite
Increased appetite
Sedation
Nausea
Headache
Sexual dysfuction
Tremor
Sweating

Saffron
3
2
5
1
2
3
0
0
0

Fluoxetine
6
5
2
0
4
6
4
4
3

P-value
0.45
0.40
0.40
1.00
0.66
0.45
0.10
0.10
0.23

Moshiri et el. study was a 6 week randomized and double-blind clinical trial that was
conducted in the outpatient clinic of Roozbeh Psychiatric. Forty adult patients that met the DSM
IV criteria for mild to moderate depression and had a baseline HAM-D scale score of at least 18
participated in this study. The patients were randomly assigned into two groups: saffron and
placebo. The saffron group received capsule petal of C. sativus 30mg/day and the placebo group
received a placebo capsule. The A psychiatrist assessed the patients at baseline and after 1, 2, 4,
and 6 weeks after the medication started. Throughout the study, the person who administered the
medications, rater and patients were blind to assignments. The data was continuous and an
unpaired student’s t-test with a two-sided P-value was used to compare the two groups at
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baseline and at the end of the trial. Results were presented as mean ± S.E.M. Differences were
considered significant with P<0.05. The changes in the HAM-D scale score at the endpoint
compared to the baseline were found to be -14.01 ± 5.53 in the crocus sativus group and -5.05 ±
4.63 in the placebo group (Table 5). The p-value was found to be P<0.0001, thus a significant
difference was observed on the change of scores of the Hamilton Depression Rating Scale at
week 6 compared to baseline in the two groups (Table 5). There were eight side effects observed
over the course of the 6-week trial, including anxiety, decreased appetite, stomach pain, tremor,
nausea, headache, sweating and heart pounding. However, there was no significant difference
between the frequency of side effects between the two groups.2
Table 5- Efficacy of crocus sativus vs. placebo
Study
Moshiri et el.

Crocus sativus
-14.01 ± 5.53

Placebo
-5.05 ± 4.63

P value
P <0.0001

DISCUSSION
Some type of limitation exists in almost any study that is conducted. Some limitations of
these saffron studies include: age limitations, lack of placebo group, using a fixed dose of
saffron, small number of participants, and short period of follow up. All three studies consisted
of adults aged 18-55, however, depression is very common in the elderly and these studies do not
include them. About 6 million Americans age 65 and older are affected with depression and
saffron could be a good alternative treatment for them, however the safety and efficacy of it has
not been studied in this age group.6 The studies all consisted of either 6-week or 8-week trial and
that is not sufficient time to asses the effectiveness of a medication for depression, therefore a
longer period of study is warranted to fully asses the effectiveness and safety of crocus sativus
for treatment of depression. A fixed dose of saffron was used in all three studies and the dosage
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that was used may not be as effective as a higher dose, or a lower dose may have fewer side
effects, however, these questions cannot be answered unless another study is done with differing
doses of saffron. Out of the three studies, only one contained a placebo group while the other two
did not. All three studies were conducted in Iran, and about 96% of world’s saffron is supplied
by Iran, and thus it is possible that there was a form of bias was present during the study.7 Due to
these limitations that are present in the current studies done, many more studies are warranted to
be conducted in order to fully asses the effectiveness and safety of saffron for the treatment of
mild to moderate depression.
CONLCUSION
In conclusion, three double-blind randomized controlled trials were evaluated in order to
answer the question whether or not crocus sativus (saffron) is as effectives as fluoxetine for the
treatment of mild to moderate depression in adults aged 18-55. Two of the studies compared the
effectiveness and safety of saffron to fluoxetine, while one study compared it to a placebo. Both
studies that compared the effectiveness of saffron concluded that it was as effective as fluoxetine
for the treatment of depression in adults aged 18-55. In the study conducted by Moshiri et el.
where saffron was compared to a placebo, it was concluded that patients that received C. sativus
experienced statistically significant benefits in their mood after 6 weeks of treatment compared
to placebo.2 However, due to the limitations of age, small number of participants, fixed dose of
saffron used, and lack of placebo group, many more studies are indicated before saffron can be
used as a treatment for depression.
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